Portfolio company Autifony therapeutics, which is pioneering the development of novel pharmaceutical treatments for hearing loss, has announced the start of a pilot study (called QuicK+fire) to evaluate its lead compound, AUT00063, in adult cochlear implant (CI) users.
Cochlear implants have been effective on patients with hearing loss, but are far from perfect. Many users struggle to understand speech, particularly in noisy environments.
Autifony’s AUT00063 is a drug that modulates voltage-gated Kv3 potassium channels, which are critical to the function of neural circuits involved in central auditory processing. It is thought that by increasing the precision and timing of neural firing, AUT00063 will enhance people’s hearing performance with their cochlear implant.